Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Natural products

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    130 result(s) found for: Natural products. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-004405-16 Sponsor Protocol Number: SNT-IV-005 Start Date*: 2016-03-16
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: External Natural History Controlled, open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone® in Leber’s Hereditary Optic Neuropathy (LHON)
    Medical condition: Leber’s Hereditary Optic Neuropathy / LHON is a maternally inherited loss of vision due to atrophy of the optic nerve. It typically presents in young adults, mostly men, as painless acute or subacu...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005207-42 Sponsor Protocol Number: 2005079 Start Date*: 2005-12-29
    Sponsor Name:Procter & Gamble Technical Centres Limited
    Full Title: A study to assess the efficacy of a combination of natural plant extracts in natural colds.
    Medical condition: Common Cold (nasopharyngitis), Upper Respiratory Tract Infection
    Disease: Version SOC Term Classification Code Term Level
    8.0 10028810 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004557-15 Sponsor Protocol Number: 08.0278-38 Start Date*: 2008-11-25
    Sponsor Name:Merckle Recordati GmbH
    Full Title: 10 days clinical pilot study to investigate the wound healing efficacy of Mirfulan® ointment (containing zinc oxide and cod liver) in an intra-individual comparison with a placebo, zinc oxide and c...
    Medical condition: healthy volunteers Mirfulan® ointment is a topical formulation for the treatment of wounds. Indications for the application of Mirfulan® are treatment of non-infectious acute and subacute skin dam...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002122-30 Sponsor Protocol Number: 1978 Start Date*: 2007-09-14
    Sponsor Name:Medical University Vienna Division of Anesthesie and Pain Management
    Full Title: The effect of different solvents of HES preparations on coagulation and platelet function (Effekt der Trägerlösung von HES Präparaten auf Blutgerinnung und Thrombozytenfunktion)
    Medical condition: treatment and prophylaxis of acute hypovolaemia and shock acute normovolaemic haemodilution
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021139 Hypovolemia LLT
    9.1 10011954 Decreased and nonspecific blood pressure disorders and shock HLGT
    9.1 10059489 Hemodilution LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004246-41 Sponsor Protocol Number: RG_13-198 Start Date*: 2015-01-26
    Sponsor Name:Sandwell and West Birmingham Hospitals NHS Trust [...]
    1. Sandwell and West Birmingham Hospitals NHS Trust
    2. University of Birmingham
    Full Title: A phase III randomised study of folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women
    Medical condition: Menopause Symptoms
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10027311 Menopause flushing LLT
    18.0 10041244 - Social circumstances 10028812 Natural menopause LLT
    18.0 10041244 - Social circumstances 10027308 Menopause PT
    18.0 10041244 - Social circumstances 10051775 Postmenopause PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003688-39 Sponsor Protocol Number: CLS003-CO-PR-002 Start Date*: 2014-11-26
    Sponsor Name:Cutanea Life Sciences
    Full Title: A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in C...
    Medical condition: Patients with at least two warts who are otherwise healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10010115 Common warts LLT
    17.1 100000004864 10035158 Plantar warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001589-25 Sponsor Protocol Number: BN29854 Start Date*: 2015-11-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multicenter, open-label, single-arm study to evaluate long term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed) BE (Completed) NL (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003548-22 Sponsor Protocol Number: LAEBBA0005 Start Date*: 2014-03-03
    Sponsor Name:Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc
    Full Title: Four Week Clinical Efficacy of An Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis
    Medical condition: Gingivitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006378-22 Sponsor Protocol Number: 230LE306 Start Date*: 2022-10-04
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants with Active Systemic Lupus Erythem...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011357-41 Sponsor Protocol Number: 112772 Start Date*: 2009-07-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the fir...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001371-20 Sponsor Protocol Number: 18-PP-03 Start Date*: 2018-06-11
    Sponsor Name:CHU de Nice
    Full Title: Study of the role of local treatments on the modulation of the microbiome in psoriatic skin
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018386-32 Sponsor Protocol Number: CC-10004-PSA-003 Start Date*: 2010-12-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000870-39 Sponsor Protocol Number: CHDR1607 Start Date*: 2017-08-21
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide i...
    Medical condition: HPV-induced genital lesions of immunocompromised and immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10018182 Genital warts LLT
    20.0 100000024086 10064455 HSIL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000001-25 Sponsor Protocol Number: OXO-001-201 Start Date*: 2021-08-06
    Sponsor Name:Oxolife S.L.
    Full Title: A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blast...
    Medical condition: Infertility treatment and fertility enhancer in women undergoing assisted reproductive techniques or natural reproduction
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) ES (Ongoing) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001555-37 Sponsor Protocol Number: CC-10004-AS-001 Start Date*: 2012-09-04
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyl...
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SK (Completed) NL (Completed) ES (Completed) PL (Completed) SE (Completed) CZ (Completed) AT (Completed) BG (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002643-23 Sponsor Protocol Number: STH19966 Start Date*: 2020-03-23
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Validation of a novel composite of skin biomarkers as a primary outcome measure for evaluating the safety of treatments for atopic dermatitis: a randomized controlled trial (phase 2) comparing the ...
    Medical condition: atopic eczema (synonym atopic dermatitis) and the adverse treatment side effect epidermal atrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003641 Atopic eczema LLT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10040799 Skin atrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003877-23 Sponsor Protocol Number: IMPROVE-MC Start Date*: 2022-03-22
    Sponsor Name:Medical University of Warsaw
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy (IMPROVE-...
    Medical condition: Myocarditis, inflammatory cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028606 Myocarditis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002168-17 Sponsor Protocol Number: BAY94-8862/16275 Start Date*: 2015-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in...
    Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10066498 Cardiac failure chronic aggravated LLT
    21.0 100000004857 10076408 Chronic kidney disease stage 1 LLT
    21.0 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005491-28 Sponsor Protocol Number: MO29594 Start Date*: 2015-06-19
    Sponsor Name:Roche Farma, S.A en nombre de F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSIST...
    Medical condition: Metastatic, Recurrent or Persistent Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PT (Completed) PL (Completed) GR (Completed) FR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004422-16 Sponsor Protocol Number: EA08-3-998 Start Date*: 2009-01-28
    Sponsor Name:Engelhard Arzneimittel GmbH & Co. KG
    Full Title: Investigation of local tolerability and efficacy of Muxan - a new topical treatment containing chloramine-T in 3 concentrations in comparison to Zovirax® in patients with Herpes simplex type 1
    Medical condition: Acute herpes labialis episodes caused by Herpes simplex virus-1 (HSV-1).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 09:25:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA